Stock Events

Stock Events

Benitec Biopharma 

$13.00
22
+$0.12+0.93% 15:15 Today

Statistics

Day High
13.47
Day Low
13
52W High
16.76
52W Low
9.85
Volume
23,202
Avg. Volume
129,329
Mkt Cap
446.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30SepExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.78
-0.59
-0.41
-0.22
Expected EPS
-0.267143
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-37.92MNet Income

Analyst Ratings

24.33Average Price Target
The highest estimate is 32.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNTC. It's not an investment recommendation.
Apple
5
AAPL
Microsoft
5
MSFT
Amazon
5
AMZN
NVIDIA
5
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.24B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Show more...
CEO
Jerel A. Banks
Employees
19
Country
United States
ISIN
US08205P2092
WKN
000A2P06Q

Listings

MU
DE
BJ93.MU
STU
DE
BJ93.STU
XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BNTC is $13.00 USD — it has increased by +0.93% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Benitec Biopharma stocks are traded under the ticker BNTC.
Is Benitec Biopharma stock price growing?▼
BNTC stock has risen by +6.73% compared to the previous week, the month change is a +3.05% rise, over the last year Benitec Biopharma has showed a +4.86% increase.
What is Benitec Biopharma market cap?▼
Today Benitec Biopharma has the market capitalization of 446.61M
When is the next Benitec Biopharma earnings date?▼
Benitec Biopharma is going to release the next earnings report on September 30, 2026.
What were Benitec Biopharma earnings last quarter?▼
BNTC earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.27 USD resulting in a +10.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Benitec Biopharma revenue for the last year?▼
Benitec Biopharma revenue for the last year amounts to 0 USD.
What is Benitec Biopharma net income for the last year?▼
BNTC net income for the last year is -37.92M USD.
How many employees does Benitec Biopharma have?▼
As of August 19, 2026, the company has 19 employees.
In which sector is Benitec Biopharma located?▼
Benitec Biopharma operates in the Health & Wellness sector.
When did Benitec Biopharma complete a stock split?▼
The last stock split for Benitec Biopharma was on July 26, 2023 with a ratio of 1:17.
Where is Benitec Biopharma headquartered?▼
Benitec Biopharma is headquartered in HAYWARD, United States.